By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Pierre Fabre Medicament 

Parc Industriel de la Chartreuse

Castres Cedex    81106  France
Phone: 33-0-5-63-71-45-00 Fax:


SEARCH JOBS


Industry
Biotechnology






Company News
Forest Laboratories, Inc. (FRX) and Pierre Fabre Medicament Announce Third Positive Phase III Study for Levomilnacipran in Patients With Major Depressive Disorder 4/26/2012 7:28:32 AM
Forest Laboratories, Inc. (FRX) and Pierre Fabre Medicament Announce Positive Phase III Results For Levomilnacipran in Patients With Major Depressive Disorder 3/7/2012 7:28:59 AM
Pierre Fabre Medicament is Granted Authorization in Australia to Market the Milnacipran JONCIA(R) to Treat Fibromyalgia 11/21/2011 11:56:20 AM
Forest Laboratories, Inc. (FRX), Pierre Fabre Medicament Announce Positive Phase III Results with Levomilnacipran in Patients with Major Depressive Disorder 7/18/2011 6:32:52 AM
Pierre Fabre Medicament And Zambon Sign Commercial Agreement In Germany 2/21/2007 5:14:34 PM
Novacea And Pierre Fabre Medicament Enter Into Partnership For The Development And Commercialization Of Oral Vinorelbine For Oncology10/19/2005 5:12:09 PM
Pierre Fabre Medicament And Merck & Co. (MRK) Sign Oncology Research Partnership And Licensing Agreement10/19/2005 5:11:19 PM
Bristol-Myers Squibb Company (BMY) And Pierre Fabre Medicament Enter Into Agreement To Develop And Commercialize Oncology Treatment Javlor(R) (vinflunine)10/19/2005 5:10:57 PM
Cypress Bioscience Inc., (CYPB) Forest Laboratories, Inc. (FRX) And Pierre Fabre Medicament Announce Development And Marketing Agreement For Milnacipran10/19/2005 5:09:39 PM
//-->